ABSCI CORP (ABSI) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -126.20M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 86.49M USD | Research and Development Expense |
| Selling, general and administration | 35.28M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-126.20M | (m) | (m) | $86.49M | $35.28M | (m) |
| 2026-03-31 | $-123.43M | (m) | (m) | $84.33M | $34.64M | (m) |
| 2025-12-31 | $-120.32M | (m) | (m) | $81.42M | $35.06M | (m) |
| 2025-09-30 | $-119.05M | (m) | (m) | $74.45M | $35.27M | (m) |
| 2025-06-30 | $-117.79M | (m) | (m) | $73.18M | $36.08M | (m) |
| 2025-03-31 | $-113.12M | (m) | (m) | $67.99M | $36.90M | (m) |
| 2024-12-31 | $-108.89M | $4.53M | (m) | $63.86M | $36.17M | -2401.59% |
| 2024-09-30 | $-103.85M | $4.21M | (m) | $57.75M | $36.67M | -2468.58% |
| 2024-06-30 | $-98.26M | $3.25M | (m) | $50.80M | $36.92M | -3023.42% |
| 2024-03-31 | $-114.53M | $5.35M | (m) | $47.65M | $36.98M | -2141.91% |
| 2023-12-31 | $-115.52M | $5.72M | (m) | $48.07M | $37.83M | -2020.20% |
| 2023-09-30 | $-111.87M | $6.94M | (m) | $47.11M | $36.26M | -1612.64% |
| 2023-06-30 | $-116.53M | $8.56M | (m) | $51.61M | $38.16M | -1361.05% |
| 2023-03-31 | $-102.43M | $6.20M | (m) | $55.74M | $39.26M | -1652.93% |
| 2022-12-31 | $-106.75M | $5.75M | (m) | $58.91M | $40.55M | -1857.49% |
| 2022-09-30 | $-111.91M | $5.64M | (m) | $63.36M | $41.99M | -1983.57% |
| 2022-06-30 | $-105.09M | $4.81M | (m) | $58.56M | $40.31M | -2183.87% |
| 2022-03-31 | $-92.89M | $4.54M | (m) | $53.36M | $34.98M | -2047.00% |
| 2021-12-31 | $-75.24M | $4.78M | (m) | $44.59M | $28.78M | -1573.36% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-13.30M | $4.78M | (m) | $11.45M | $5.50M | -278.26% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |